Intra- and Extracellular Activities of Trimethoprim-Sulfamethoxazole against Susceptible and Multidrug-Resistant Mycobacterium tuberculosis
2014 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 58, no 12, 7557-7559 p.Article in journal (Refereed) Published
We investigated the activity of trimethoprim-sulfamethoxazole (SXT) against Mycobacterium tuberculosis, the pathogen that causes tuberculosis (TB). The MIC distribution of SXT was 0.125/2.4 to 2/38 mg/liter for the 100 isolates tested, including multi- and extensively drug-resistant isolates (MDR/XDR-TB), whereas the intracellular MIC90 of sulfamethoxazole (SMX) for the pansusceptible strain H37Rv was 76 mg/liter. In an exploratory analysis using a ratio of the unbound area under the concentration-time curve from 0 to 24 h over MIC (fAUC(0-24)/MIC) using greater than= 25 as a potential target, the cumulative fraction response was greater than= 90% at doses of greater than= 2,400 mg of SMX. SXT is a potential treatment option for MDR/XDR-TB.
Place, publisher, year, edition, pages
American Society for Microbiology , 2014. Vol. 58, no 12, 7557-7559 p.
IdentifiersURN: urn:nbn:se:liu:diva-112994DOI: 10.1128/AAC.02995-14ISI: 000345221000065PubMedID: 25246405OAI: oai:DiVA.org:liu-112994DiVA: diva2:779163
Funding Agencies|Swedish Society of Medicine [SLS 169241]; Marianne and Marcus Wallenberg Foundation; Swedish Heart and Lung Foundation (Oscar II Jubilee Foundation); Swedish Society of Antimicrobial Chemotherapy2015-01-122015-01-082015-03-12